SCHEMBL7248356

SCHEMBL7248356

S=CNc1ccc(N=Nc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
MAPT P10636 11/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KMT2A Q03164 10/20 0.46
MEN1 O00255 9/20 0.46
HPGD P15428 2/20 0.46
HTT P42858 2/20 0.45
PKM P14618 1/20 0.45
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 4/20 0.42
MAPK1 P28482 3/20 0.42
HSP90AA1 P07900 1/20 0.42
TSHR P16473 2/20 0.42
CYP1A1 P04798 1/20 0.42
CYP1B1 Q16678 1/20 0.42
HSD17B10 Q99714 1/20 0.41
TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7248354 1.00 ALDH1A1 (0.50) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL57469 0.79
SCHEMBL19175924 0.79 ALDH1A1 (0.50) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL11695263 0.79 ALDH1A1 (0.64) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL8764231 0.76 ALDH1A1 (0.35) ALDH1A1
SCHEMBL22211293 0.76 KDM4E (0.32) KMT2AKDM4ECYP2D6
SCHEMBL1269897 0.76 ALDH1A1 (0.43) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7361947 0.76 ALDH1A1 (0.62) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL21023910 0.74 ALDH1A1 (0.92) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL21024214 0.74 ALDH1A1 (0.92) ALDH1A1MAPTRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562840-B1 Non-peptidic inhibitors of proteolytic enzymes such as urokinase 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-05-13 US disclosed
EP-1054886-B1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS DIMENSIONAL PHARM INC (US) 2002-09-04 EP disclosed
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP disclosed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US disclosed
WO-2000047194-A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR DIMENSIONAL PHARM INC (US) 2001-05-31 WO disclosed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 ALDH1A1 3209/4885MAPT 3492/4885RAB9A 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.